+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitor therapy and potential long-term harm



Proton pump inhibitor therapy and potential long-term harm



Current Opinion in Endocrinology, Diabetes, and Obesity 21(1): 3-8



This review summarizes the recent literature on the potential side-effects of proton pump inhibitors (PPIs) and known interactions with the metabolism/absorption of other drugs. Data confirm that PPIs are a very well tolerated drug class. Their high safety, efficacy and wide distribution lead to overuse, inappropriate dosage or excessive duration of treatment. Despite the absorption of micronutrients or other plausible effects on the development of bacterial infections linked to PPI-induced hypochlorhydria, it is difficult to demonstrate an association between PPI and specific symptoms. A possible negative effect of PPIs on bone integrity appears weak, but hypomagnesemia is likely a PPI drug class effect. A higher risk of Clostridium difficile infection and other infectious diseases such as small intestinal bacterial overgrowth and spontaneous bacterial peritonitis remain controversial in PPI users. However, the careful use of PPIs in cirrhotic or otherwise fragile patients is mandatory. Short-term or long-term PPI use may trigger microscopic colitis, and the management of this condition may include PPI withdrawal. The effect of PPIs on stimulating exocrine or endocrine gastric cell proliferation is poorly understood. A diagnostic delay or masking of diseases such as gastrinoma is difficult to evaluate. Short-term standard dose PPI treatment is low risk. Long-term PPI use may complicate health conditions by various mechanisms linked to PPIs and/or to hypochlorhydria.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260253

Download citation: RISBibTeXText

PMID: 24310148

DOI: 10.1097/MED.0000000000000031


Related references

Proton pump inhibitor - side effects and complications of long-term proton pump inhibitor administration. Zeitschrift für Gastroenterologie 55(1): 63-74, 2017

Long-term Use of Proton-Pump Inhibitor Therapy. Gastroenterology and Hepatology 4(5): 322-325, 2008

Discontinuation of Long-Term Proton Pump Inhibitor Therapy. American Journal of Therapeutics 2018, 2018

Is there a dark side to long-term proton pump inhibitor therapy?. American Journal of Therapeutics 15(6): 536-542, 2009

Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture. Yearbook of Endocrinology 2008: 206-208, 2008

Adverse effects of long-term proton pump inhibitor therapy. Digestive Diseases and Sciences 56(4): 931-950, 2011

Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24): 2947-2953, 2006

Long-term proton pump inhibitor therapy: beware of vitamin B 12 deficiency. Mmw Fortschritte der Medizin 156(5): 34, 2014

Helicobacter pylori infection and long term proton pump inhibitor therapy. Gut 53(1): 5-7, 2004

Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?. Orvosi Hetilap 154(26): 1005-1009, 2013

The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine 49(3): 606-610, 2016

Adverse effects of long-term proton-pump inhibitor therapy on adults. Orvosi Hetilap 159(19): 735-740, 2018

Does Long-Term Proton Pump Inhibitor Therapy Affect the Health of Gut Microbiota?. Gut and Liver 10(6): 865-866, 2016

A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety. Clinical and Translational Science 10(5): 387-394, 2017

Long-term proton pump inhibitor therapy and risk of hip fracture (vol 296, pg 2947, 2006). JAMA (Journal of the American Medical Association) 297(5): 470, 2007